Zunveyl, an oral medication, is a better-tolerated version of galantamine for managing mild to moderate Alzheimer's symptoms.

Johnson & Johnson, already a big player in neuroscience drugs, is adding to its portfolio and pipeline with a deal to acquire ...

New expensive but disease-modifying treatments are expected to foster Alzheimer’s disease market growth globally, according ...

More than 58.5 million American adults (1 in 4) have arthritis, according to the Centers for Disease Control ... quality of ...

The agency expects to issue a decision by Aug. 31, and it is slated to decide on maintenance dosing for an intravenous form of the drug later this month.

Treatment with an oral allosteric modulator was nonsuperior to placebo at 6 weeks in adults with Parkinson’s disease whose ...

The finding has implications for all of us, write Harvard physician-researchers Christopher Worsham and Anupam Jena.

Dementia cases in the U.S. are expected to double by 2060, with an estimated one million people diagnosed per year, according ...

Altruism values for treatments of rare, severe pediatric diseases have not been estimated. This study found the altruism value for a hypothetical new Duchenne muscular dystrophy treatment to be $80 ...

Annovis Bio Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer’s disease ...

The enduring scientific interest in the brain is highlighted by the donation of Charles Babbage’s brain in 1871. Babbage’s ...

Sleep disturbances encompass a broad range of disorders, such as insomnia, restless legs syndrome, parasomnias, sleep-disordered breathing, daytime ...